Blood Eosinophil Level to Predict Chronic Obstructive Pulmonary Disease Clinical Outcomes: Not Ready Yet

COPD (chronic obstructive pulmonary disease) is a leading cause of death and disability worldwide—by 2020, it became the third most common reason people die globally, and its burden remains high today. For patients and doctors, finding reliable ways to predict COPD outcomes (like sudden flare-ups or pneumonia) and tailor treatments is critical. One promising but controversial candidate? Blood eosinophils—white blood cells that play a key role in the immune system. Recent research suggests these cells might link to COPD severity, treatment response, and infection risk. But as Cheng-Sen Cai and Jun Wang from the Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine (Jinan, China) explain, the science isn’t settled yet.

What Are Eosinophils, and How Do They Relate to COPD?

Eosinophils are part of the body’s defense against infections and inflammation. When the lungs are inflamed (as in COPD), the bone marrow releases more eosinophils into the bloodstream. These cells then travel to the airways via chemical signals, where they help kickstart the immune response. For years, researchers have wondered if blood eosinophil levels could act as a “biological marker” to predict how COPD will progress or how well patients will respond to treatment.

Recent Findings—And Conflicts

Several studies have linked blood eosinophils to three key COPD outcomes:

Acute Exacerbations: Sudden worsenings of COPD symptoms (like coughing, wheezing, or shortness of breath) that often require hospitalization. Some research suggests higher eosinophil levels mean a greater risk of flare-ups.
Pneumonia: A common and dangerous complication of COPD. Lower eosinophil levels might be tied to more frequent pneumonia, possibly because eosinophils help clear infections before they turn severe.
Response to Inhaled Corticosteroids (ICS): These anti-inflammatory drugs are mainstays of COPD treatment. Some studies found patients with high eosinophils respond better to ICS (when combined with airway openers like long-acting beta-2 agonists, or LABA).

But here’s the catch: results are often contradictory. For example:

A 2015 study in Lancet Respiratory Medicine found that combining ICS + LABA cut flare-ups by 19% in patients with eosinophils above 2% (compared to LABA alone).
Yet a 2016 analysis of the Inhaled Steroids in Obstructive Lung Disease in Europe trial found the opposite: patients with eosinophils below 2% had fewer flare-ups (1.32 vs. 1.63 per year).
A 2016 New England Journal of Medicine study went further: it compared two common COPD treatments (ICS + LABA vs. LABA + long-acting muscarinic antagonists, or LAMA) and found the LAMA combo worked better—regardless of eosinophil levels.

The link to pneumonia is equally messy. A 2016 meta-analysis of 10 trials (over 10,000 patients) found people with eosinophils below 2% had a slightly higher pneumonia risk (3.7% vs. 3.2%). But other studies—including one on severe COPD patients (with less than 50% lung function)—found no connection between eosinophils and pneumonia.

Why Do Results Vary So Much?

Cai and Wang point to six key reasons for the confusion:

Different Study Populations: Most trials focus on moderate-to-severe COPD, but few include patients with severe or life-threatening disease. Severity matters—what works for a patient with mild COPD might not help someone with advanced disease.
Treatment Differences: Studies test different medications (ICS alone, ICS + LABA, LABA + LAMA) and doses. Eosinophil levels can change depending on which drugs patients take.
Unstandardized Cutoff Values: There’s no agreement on what counts as “high” or “low” eosinophils. Some studies use 2% (of total white blood cells) as a threshold; others use 340 cells per mL. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline suggests 100 cells/mL (little ICS benefit) and 300 cells/mL (more benefit)—but even this is debated.
Fluctuating Eosinophil Levels: Eosinophil counts aren’t always stable. A 2014 study tracked 1,485 patients over three years and found nearly half (49%) had levels that bounced above and below the 2% cutoff—meaning a single blood test might not be reliable.
Inclusion/Exclusion Criteria: Some studies exclude patients with asthma-COPD overlap (a condition where asthma and COPD coexist), while others don’t. Since asthma also raises eosinophils, this can skew results.
Post Hoc Analyses: Most studies reuse data from existing trials (called “post hoc” analyses) instead of running new, controlled experiments designed to test eosinophils directly. This makes results less robust.

What Does This Mean for Patients?

Eosinophils are promising—but not ready for clinical use yet. They might one day help doctors decide who needs more aggressive treatment or who will respond to ICS. But today, there’s too much inconsistency to rely on them. Key questions remain:

How exactly do eosinophils affect COPD progression?
What’s the best cutoff value for guiding treatment?
How do other factors (like smoking history, age, or comorbidities) interact with eosinophils?

Conclusion

As Cai and Wang emphasize, more research is needed—especially basic science to understand eosinophils’ molecular role in COPD and large, well-designed trials to test their value as a marker. Until then, eosinophils will stay a “watch this space” topic—not a tool doctors can use to guide care.

This study was supported by the China Song Qingling Foundation for Clinical Research of Respiratory Diseases Public Welfare Fund for Chronic Obstructive Pulmonary Disease (No. 2018MZFS-034). The authors report no conflicts of interest.

doi.org/10.1097/CM9.0000000000000447

Was this helpful?

0 / 0